{'fraction_non_alphanumeric': 0.028455284552845527, 'fraction_numerical': 0.013550135501355014, 'mean_word_length': 5.598214285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Topical 5‐ALA photodynamic therapy for the treatment of cutaneous T‐cell lymphoma

Summary Therapeutic options for cutaneous T cell lymphoma (CTCL) include topical steroids, topical chemotherapy and phototherapy. Patients with limited disease that is unresponsive to these therapies present a particular challenge. We report successful treatment of a patient with two plaques of CTCL using topical photodynamic therapy (PDT). 5‐aminolaevulinic acid (5‐ALA) was applied 6–24 h preillumination with 100 J/cm2 red light. Treatment was repeated on four occasions with clinical and histological clearance. ALA–PDT may be a useful addition to the therapeutic options for CTCL. Further studies are required to define optimal treatment protocols.